Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?
G
G
Giovannoni
D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012333:RNA, Messenger / Q000096:biosynthesis; D016896:Treatment Outcome
D007155:Immunologic Factors; D012333:RNA, Messenger; D016899:Interferon-beta